Articles tagged "Liver transplantation"

2020 American Transplant Congress
Changes in Risk Factors for Infections Post Liver Transplantation – A 16-Year Analysis
I. Bajjoka, S. Serra, J. Mourad, M. Callaghan, C. Crombez, S. Foley, M. Abouljoud
Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Infections are common cause of morbidity and mortality post liver transplant (LT). Risk factors are related to donor and recipient factors, including cold ischemia…
2020 American Transplant Congress
Analysis of the Mechanism of Liver-Resident NK Cells Activity via the Aryl Hydrocarbon Receptor
K. Sato, M. Ohira, Y. Imaoka, H. Ohdan
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: Tumor recurrence is the main limitation of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). We previously reported an adoptive immunotherapy approach that…
2020 American Transplant Congress
Safety and Patency of Inferior Vena Cava Reconstruction with Artificial or Autologous Blood Vessels During Liver Autotransplantation: Five-Year Results from a Prospective Cohort Study of 73 Cases
T. Wang, X. Yang, W. Wang
Department of Liver Surgery & Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China
*Purpose: To compare the short-term and long-term effects of artificial blood vessels and autologous blood vessels to reconstruct the retrohepatic inferior vena cava (IVC) in…
2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
K. Nunez, T. Sandow, P. Thevenot, A. Cohen
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…
2020 American Transplant Congress
In a Murine Model of Acetaminophen-Mediated Liver Injury, Tubastatin-a, An Hdac6-Specific Inhibitor, Improves Survival and Decreases Hepatocellular Injury
C. S. OBrien¹, P. T. Hernandez¹, S. J. Concors¹, L. N. Krumeich¹, Z. Wang¹, G. Ge¹, T. Bhatti², A. Kozikowski³, W. Hancock², M. H. Levine¹
¹Department of Surgery, University of Pennsylvania, Philadelphia, PA, ²Department of Pathology, Children's Hospital of Pennsylvania, Philadelphia, PA, ³Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL
*Purpose: Tylenol (APAP) toxicity, due to its narrow therapeutic window, is the leading cause of acute liver failure in the United States, resulting in approximately…
2020 American Transplant Congress
Cross-Validation of Performance-Based Frailty against Daily Step Count from Personal Activity Trackers – Refining Prehabilitation Tools in Liver Transplant Candidates
M. A. Hassan¹, M. A. Dunn¹, P. M. Bloomer¹, A. H. Gougol¹, M. Serper², D. R. Jorgensen¹, A. Duarte-Rojo¹
¹Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: The AST proposed a toolkit to identify frailty in liver transplant (LT) candidates, including the liver frailty index (LFI) and 6-min walk test (6MWT).…
2020 American Transplant Congress
Therapeutic Targeting of Bile Acid Metabolism Ameliorates Liver Ischemia/Reperfusion Injury
M. Ni¹, D. Jin², T. Lu², J. Zhang¹, R. Busuttil¹, J. Kupiec-Weglinski¹, J. Zhang², Y. Zhai¹
¹Dumont-UCLA Transplant Center, Los Angeles, CA, ²Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
*Purpose: Farnesoid X receptor (FXR) is the major nuclear receptor of bile acids, which is also involved in the regulation of innate immune responses. As…
2020 American Transplant Congress
Utilization of Hepatitis C Viremic Donors in Liver Transplantation. A Single Center Experience
R. Cohen, N. Chandolias*, K. Khanmoradi, S. Campos, H. Kaul, J. Walter, S. Rossi, V. Navarro, R. Zaki
Department of Digestive Disease and Transplantation, Albert Einstein Medical Center, Philadelphia, PA
*Purpose: The evolution of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), in the setting of the well recognized organ shortage and the…
2020 American Transplant Congress
Hepatocellular Carcinoma Recurrence after Severe Acute Cellular Rejection
M. Najjar¹, O. Perez¹, K. Bruestle¹, A. Qian¹, P. Jiang¹, A. Srivastava¹, Y. Saenger¹, E. Verna¹, E. Zheng¹, A. Mathur¹, A. Griesemer¹, K. Halazun², B. Samstein², T. Kato¹, J. Emond¹
¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The interplay between acute cellular rejection (ACR), immunosuppression and hepatocellular carcinoma (HCC) recurrence in patients who underwent liver transplantation (LT) for HCC is still…
2020 American Transplant Congress
Changes in the Development and Incidence of Bacterial Infections – A 16-Year Analysis
I. Bajjoka, S. Serra, M. Jade, M. Callaghan, C. Crombez, S. Foley, M. Abouljoud
Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Bacterial infections may occur at any time but mostly within the first month post-transplant. However, since recent advances in transplant there has not been…